Swedish Orphan Biovitrum
Search results
Genmab is an international biotech company specializing in antibody therapeutics for the treatment of cancer and other serious diseases.
Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. Danish investment firm BankInvest, under Florian Schönharting, provided the seed investment for the company to start up in Copenhagen. Like Medarex, Genmab began work producing monoclonal antibodies for life-threatening or debilitating ...
Discover Genmab, an international biotechnology company that creates,develops and commercializes and commercializes antibody therapeutics to treat cancer and other serious diseases.
May 29, 2024 · Genmab's antibody-based therapeutics have the potential to transform the treatment of cancer and other serious diseases. Explore our investigational medicines pipeline.
Genmab is using artificial intelligence (A.I.) and machine learning to turbocharge innovation and transform how it researches, develops novel antibody therapies with the goal to make an impact on the lives of patients.
Genmab is a biotech company that creates antibody-based treatments for cancer and other serious diseases.
Genmab is an international biotechnology company that develops innovative antibody products, with the vision that our knock-your-socks-off antibody treatments TM transform the treatment of cancer and other serious diseases.
Genmab’s antibody technology platforms are the foundation for novel therapeutics with the aim of transforming how cancer and other serious diseases are treated.
Apr 3, 2024 · The addition of Rina-S to Genmab’s portfolio will enable Genmab to deepen its presence in the gynecologic oncology space and establish a firm foundation in solid tumors. As a potential best-in-class ADC, Rina-S aims to address a broader patient population than first-generation FRα-targeted ADCs.
Genmab's history has been powered by a dedication to antibody-based therapeutics. Learn more about our key accomplishments, milestones and moments
